Schreiber Martin A, Holcomb John B, Hedner Ulla, Brundage Susan I, Macaitis Joseph M, Hoots Keith
Michael E. DeBakey Department of Surgery, Baylor College of Medicine, University of Texas at Houston, Houston, Texas, USA.
J Trauma. 2002 Aug;53(2):252-7; discussion 257-9. doi: 10.1097/00005373-200208000-00011.
Recombinant factor VIIa (rFVIIa) has been used to decrease bleeding in a number of settings including hemophilia, liver transplantation, intractable bleeding, and cirrhosis. Experience in the trauma setting is limited. This study was performed to determine whether rFVIIa would reduce bleeding after a grade V liver injury in hypothermic, dilutionally coagulopathic pigs when used as an adjunct to abdominal packing and to determine whether increasing the dose of the drug increased its hemostatic efficacy.
Thirty animals were randomized to receive 180 microg/kg of rFVIIa, 720 microg/kg of rFVIIa, or vehicle buffer control. After laparotomy and splenectomy, animals underwent a 60% blood volume isovolemic exchange transfusion with 5% human albumin. The animals' temperature was maintained at 33 degrees C and a standardized grade V liver injury was made with a liver clamp. Thirty seconds after injury, the abdomen was packed with laparotomy sponges, resuscitation was initiated, and blinded therapy was given. Animals were resuscitated to their baseline mean arterial pressure and the study was continued for 2 hours. Serial coagulation parameters were measured at the temperature they were drawn. After the study period, surviving animals were killed, posttreatment blood loss was measured, and an autopsy was performed.
Ten animals were randomized to each group. After administration of study drug, factor VII clotting activity (FVII:C) was higher in the 720 microg/kg group than in the 180 microg/kg group (p < 0.01). FVII:C was higher in both treatment groups than in the control group (p < 0.01). The mean prothrombin time was shorter in the treatment groups than in the control group (p < 0.05). Mean arterial pressure was lower in the control group than in the treatment groups throughout the study (p < 0.01). Mean blood loss was less in the treatment groups than in the control group (p = 0.03). Mortality was not different between groups. There were no differences between the groups that received rFVIIa in any measured parameters except for FVII:C. Liver injuries were similar between groups and there was no evidence of microthrombosis on lung histology.
rFVIIa reduces blood loss in hypothermic, dilutionally coagulopathic pigs with grade V injuries when used as an adjunct to packing. Increasing the dose does not enhance the hemostatic effect.
重组凝血因子VIIa(rFVIIa)已被用于多种情况下减少出血,包括血友病、肝移植、难治性出血和肝硬化。在创伤情况下的经验有限。本研究旨在确定rFVIIa作为腹部填塞的辅助手段时,是否能减少低温、稀释性凝血病猪V级肝损伤后的出血,并确定增加药物剂量是否能提高其止血效果。
30只动物被随机分为接受180μg/kg的rFVIIa、720μg/kg的rFVIIa或赋形剂缓冲液对照组。剖腹术和脾切除术后,动物用5%人白蛋白进行60%血容量的等容血液交换输血。动物体温维持在33℃,用肝夹造成标准化的V级肝损伤。损伤后30秒,用剖腹术海绵填塞腹部,开始复苏,并给予盲法治疗。将动物复苏至其基线平均动脉压,并持续研究2小时。在采血时的温度下测量系列凝血参数。研究期结束后,处死存活的动物,测量治疗后失血量,并进行尸检。
每组10只动物随机分组。给予研究药物后,720μg/kg组的凝血因子VII凝血活性(FVII:C)高于180μg/kg组(p<0.01)。两个治疗组的FVII:C均高于对照组(p<0.01)。治疗组的平均凝血酶原时间短于对照组(p<0.05)。在整个研究过程中,对照组的平均动脉压低于治疗组(p<0.01)。治疗组的平均失血量少于对照组(p = 0.03)。各组之间死亡率无差异。除FVII:C外,接受rFVIIa的组在任何测量参数上均无差异。各组之间肝损伤相似,肺组织学上没有微血栓形成的证据。
rFVIIa作为填塞的辅助手段时,可减少低温、稀释性凝血病的V级损伤猪的失血量。增加剂量并不能增强止血效果。